Compare Medpace Holdings Inc (MEDP) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Raymond James Financial, Inc. — how do they compare? Medpace Holdings Inc trades at $531.97 (market cap $15.08B), while Raymond James Financial, Inc. trades at $168.67 (market cap $32.80B). The key difference: Raymond James Financial, Inc. is far larger — about 2.2× Medpace Holdings Inc's market cap, and Raymond James Financial, Inc. pays a 1.28% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | RJF | |
|---|---|---|
Market Cap | $15.08B | $32.80B |
Sector | Technology | Financials |
52-Week High | $620.59 | $176.43 |
52-Week Low | $308.88 | $140.89 |
Enterprise Value | $14.55B | — |
Dividend Yield | — | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Raymond James Financial (RJF) trades at $168.23, down slightly by 0.08% on the day. The stock shows a bullish technical trend with moving averages supporting upside momentum, while recent earnings beats and steady revenue growth highlight fundamental strength. Analyst consensus is positive with a $176.83 price target, and the company declared a $0.54 dividend payable in July 2026.
Outlook remains favorable given consistent earnings performance and strong analyst support, though rising expenses and market volatility pose risks. The stock's current valuation metrics, including a P/E of 15.9, suggest room for growth if execution continues. Key catalysts include upcoming Q2 2026 earnings and sustained advisor network expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
